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Purpose: To compare the intraocular pressure- (IOP-) lowering efficacy of fixed combinations 
travoprost 0.004%/timolol 0.5% and dorzolamide 2%/timolol 0.5% in patients with ocular 
hypertension or open-angle glaucoma.
Methods: In this prospective, multicenter, double-masked, randomized clinical trial, 319 
qualifying patients received either travoprost/timolol once daily in the morning (n = 157) or 
dorzolamide/timolol twice daily (n = 162). IOP was assessed morning and evening at 2 and 
6 weeks. The primary outcome measure was mean diurnal IOP.
Results: Baseline mean IOP values were similar between groups. Mean pooled diurnal 
IOP was significantly lower in the travoprost/timolol group (16.5 mmHg ± 0.23) than in the 
dorzolamide/timolol group (17.3 mmHg ± 0.23; P = 0.011). Mean IOP was significantly lower 
in the travoprost/timolol group compared to the dorzolamide/timolol group at the 9 AM time 
point both at Week 2 (P = 0.006) and Week 6 (P = 0.002). The travoprost/timolol combination 
produced mean IOP reductions from baseline of 35.3% to 38.5%, while the dorzolamide/timolol 
combination produced mean IOP reductions from baseline of 32.5% to 34.5%.
Conclusions: The fixed combination travoprost 0.004%/timolol 0.5% dosed once daily 
in the morning demonstrated superior mean diurnal IOP-lowering efficacy compared to 
dorzolamide 2%/timolol 0.5% dosed twice daily in patients with ocular hypertension or 
open-angle glaucoma.
Keywords: dorzolamide, fixed combination, glaucoma, IOP-lowering therapy, timolol, 
travoprost
Introduction
Glaucoma is one of the main causes of blindness and irreversible visual deterioration 
worldwide. To date, the only treatment that can effectively prevent the development1 
and progression2 of glaucoma is reduction of intraocular pressure (IOP). The most 
commonly used way of achieving IOP reduction is the use of topical IOP-lowering 
medications. Monotherapy is frequently not sufficient for reaching the preset target 
IOP; therefore, many patients require more than one medication to achieve adequate 
IOP reduction.1
Several fixed combinations of commonly used IOP-lowering medications have been 
developed and are available in various markets worldwide. Most fixed combinations 
contain timolol, as it can be dosed either once or twice daily and can be combined 
with prostaglandin analogues, adrenergic agonists, and carbonic anhydrase inhibitors. 
Compared to concomitant dosing with individual constituents, these combinations 
offer the convenience of fewer drops per day, fewer bottles to handle by the patients, Clinical Ophthalmology 2009:3 630
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reduced exposure to preservatives, and elimination of the 
washout effect of multiple drops.3
Travoprost 0.004%/timolol 0.5% (DuoTrav®; Alcon 
Laboratories, Fort Worth, Texas, USA) and dorzolamide 
2%/timolol 0.5% (CosoptTM; Merck and Co., Whitehouse 
Station, New York, USA) are different fixed combinations, 
but both contain timolol 0.5%. To date, no comparative 
clinical studies have been published with these two agents. 
The purpose of this study was to compare the IOP-lowering 
efficacy and safety of these two fixed combinations in patients 
with ocular hypertension or open-angle glaucoma.
Methods
This was a prospective, multicenter, randomized, double-
masked clinical trial that was approved by the Ethics Committee 
of each individual study site and was conducted in 
accordance with the tenets of the Declaration of Helsinki. 
All participating patients provided written informed consent 
before they enrolled in the study.
Patients
Eligible patients were male or female patients 18 years of age or 
older, of any race, diagnosed with open-angle glaucoma (with 
or without pseudoexfoliation or pigment dispersion component) 
or ocular hypertension. The patients had to be under treatment 
with one or more topical IOP-lowering drugs and, in the opinion 
of the investigator, would have benefited from treatment with a 
combination therapy. To be eligible, patients must have had at 
least one eye that reached an IOP of 24 mmHg at 9 AM and 
21 mmHg at 4 PM at both eligibility visits. IOP must not have 
exceeded 36 mmHg (or 30 mmHg at study sites in Germany, 
as per a specific local requirement) at any time point. Contact 
lens wearers were eligible if they removed their lenses before 
instilling study medication and did not replace the lenses for 
at least 15 minutes after instillation.
Exclusion criteria were history of chronic, recurrent, 
or current inflammatory eye diseases or progressive retinal 
diseases; history of incisional ocular surgery or ocular trauma 
within 6 months before the study; ocular laser treatment or 
ocular surgery, ocular infection within 3 months; history of 
hypoglycemia or uncontrolled diabetes; contraindication to any 
study medication; advanced glaucoma (cup-disc ratio  0.8 or 
central visual field loss); or any ocular abnormalities precluding 
accurate applanation tonometry. In addition, patients were 
excluded if they required systemic glucocorticoid therapy, 
could not safely discontinue all IOP-lowering therapies for up 
to 28 days before the first of two eligibility visits conducted 
1 week apart, or used any IOP-influencing medication within 
30 days before enrollment. Women of childbearing potential 
(not surgically sterilized at least 3 months prior the study or 
not postmenopausal for at least 2 years) were not excluded 
if they were using a reliable form of birth control; a urine 
pregnancy test was performed after the completion of the 
second eligibility visit, before randomization, and then 
repeated at the exit visit in these patients.
schedule of visits and assessments
Potential candidates for the study received information related 
to the study and were provided the opportunity to discuss 
the study requirements with the investigator. Patients who 
agreed to participate and gave their consent attended a screen-
ing visit, at which time demographics and medical history 
were collected and reviewed, visual acuity was assessed, 
IOP was measured with Goldmann tonometry, gonioscopy 
and automated threshold perimetry were performed, and 
anterior and posterior segment evaluation was conducted. 
Patients who qualified were requested to discontinue their 
current IOP-lowering medications according to the following 
schedule: 5 days for miotics and carbonic anhydrase inhibitors 
(both topical and oral); 14 days for α and α/β-agonists; and 
28 days for β-blockers, prostaglandin analogues, and fixed 
combination products. Following washout, two separate 
eligibility visits were performed one week apart. At each 
of these eligibility visits, the IOP criteria described above 
had to be met, interim history was recorded, visual acuity 
assessed, and slit-lamp examination of the anterior segment 
was performed. At the completion of the eligibility visits, 
qualified patients were randomized in a 1:1 ratio to receive 
either travoprost 0.004%/timolol 0.5% fixed combination 
once daily at 9 AM and timolol vehicle once daily at 9 PM, or 
dorzolamide 2%/timolol 0.5% fixed combination twice daily 
at 9 AM and 9 PM, in both eyes. Patients started their study 
medication on the evening of the second eligibility visit, and 
continued their treatment for six weeks. Patients were provided 
with “morning 9 AM bottles” and “evening 9 PM bottles” for 
masking purposes. The study visits were scheduled 2 weeks 
and 6 weeks after randomization. At the Week 2 and Week 6 
visits, patients arrived at 9 AM and refrained from morning 
administration of the study medication until visual acuity 
was assessed, IOP measured, slit-lamp examination of the 
anterior segment performed, and any adverse event recorded. 
Study medication was then instilled, and patients returned at 
4 PM for the afternoon IOP measurement. Dilated fundus 
examination for all patients and repeated urine pregnancy 
testing for patients of childbearing potential were conducted 
at the Week 6 visit prior to study exit.Clinical Ophthalmology 2009:3 631
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Data analysis and statistics
The primary statistical objective of this study was to examine 
the IOP-lowering efficacy of travoprost 0.004%/timolol 0.5% 
dosed once daily compared to that of dorzolamide 2%/timolol 
0.5% dosed twice daily. One eye per patient was included in 
the analysis, even if both eyes were dosed. If only one eye 
was dosed, the dosed eye was selected for the analysis; if both 
eyes were dosed, the worst evaluable eye was designated study 
eye and selected for the analysis. If both eyes met eligibility 
criteria, the eye with the higher IOP at 9 AM averaged over 
both eligibility visits was selected as the study eye. If IOP 
of both eyes was equal at 9 AM, the eye with higher IOP 
measured at 4 PM was used. If IOP was equal for both 
eyes at 4 PM, the right eye was designated the study eye. 
The primary efficacy endpoint was mean IOP, which was 
evaluated at 4 time points: 9 AM and 4 PM at each of the 2 
follow-up visits (Week 2 and Week 6). At each time point, at 
least 2 IOP measurements were taken. If the 2 measurements 
for the same eye differed by 4 mmHg or less, the average IOP 
for that eye was used. If the 2 measurements differed more 
than 4 mmHg, a third measurement was taken and used as 
the IOP for that eye.
Hypothesis tests were performed using a repeated 
measures analysis of variance and the primary inference 
was based on the comparisons of mean IOP between the two 
treatment groups across the four on-therapy visits and time 
points using the intent-to-treat dataset. A chi square test of 
independence (or Fisher’s exact test if one or more expected 
cell frequencies were 5) was used to assess differences 
between treatment groups for each demographic character-
istic. Mean IOP change from baseline was estimated using a 
repeated measures analysis of variance. Descriptive statistics 
were calculated for IOP, IOP change from baseline, and IOP 
percent change from baseline. To evaluate the IOP-lowering 
efficacy throughout the day, IOP was pooled across both 
time points at each of the two follow-up visits, and the mean 
value obtained was defined as combined diurnal IOP. The 
term diurnal is used here to indicate the awake period during 
the day, rather than a 24-hour period of time, as would be 
indicated by a diurnal IOP curve.
With 150 patients per group planned, this study had a 96% 
power to detect a 1.5 mmHg difference between groups, based 
on an assumed common standard deviation of 3.5 mmHg and 
a Type I error of α = 0.05.
Results
A total of 319 adult patients were enrolled in this study and 
randomized to receive either travoprost/timolol (n = 157) or 
dorzolamide/timolol (n = 162). All 319 participants were 
included in the safety analysis. Three patients were excluded 
from the intent-to-treat (ITT; n = 316) analysis due to lack 
of data on-therapy, and 6 additional patients were excluded 
from the per-protocol (PP; n = 310) analysis, due to protocol 
deviations (inadequate time interval from dosing to IOP 
reading, no qualifying IOP at entry, and intraocular surgery 
less than 6 months prior to study entry). Results of ITT 
analyses are presented in this report and were confirmed in 
PP analyses. Baseline patient demographic information for the 
safety population is provided in Table 1. No significant differ-
ences were observed between treatment groups in any of the 
demographic characteristics; the same was true for the ITT and 
PP population data sets. The age (mean ± SD) of patients in 
the safety population was 61.7 ± 10.8 years. The IOP-lowering 
medications taken by patients prior to study enrollment are 
presented in Table 2, with both treatment groups showing 
a similar breakdown among the therapy classifications.
Mean diurnal IOP values (pooled across 9 AM and 
4 PM time points) are illustrated in Figure 1. Baseline 
mean diurnal IOP values were similar in the travoprost/
timolol (26.0 ± 0.18 mmHg) and the dorzolamide/timolol 
(26.1 ± 0.18 mmHg) groups (P = 0.818). Both treatments 
reduced diurnal IOP at Weeks 2 and 6 from baseline; however, 
treatment with travoprost/timolol resulted in 0.8 mmHg 
lower mean diurnal IOP than that with dorzolamide/timolol 
at each of the two on-therapy visits (P  0.05). A similar 
difference was observed for travoprost/timolol compared 
with dorzolamide/timolol when pooled across the two visits 
(combined; 16.5 ± 0.23 mmHg vs 17.3 ± 0.23 mmHg, 
respectively; P = 0.011).
Mean IOP values at the individual time points at baseline, 
Week 2, Week 6 and Combined (Week 2 + Week 6) are 
presented in Table 3. Baseline mean IOP values were similar 
in the travoprost/timolol and the dorzolamide/timolol groups 
both at 9 AM (26.9 ± 0.19 mmHg and 27.0 ± 0.19 mmHg, 
respectively, P = 0.652) and 4 PM (25.1 ± 0.19 mmHg 
in both groups, P = 0.987). At 9 AM (approximately 
24 hours after dosing with travoprost/timolol), mean IOP 
was significantly lower in the travoprost/timolol group 
than in the dorzolamide/timolol group, both at Week 2 
(17.0 ± 0.26 mmHg vs 18.0 ± 0.25 mmHg; P = 0.006) and 
Week 6 (16.6 ± 0.26 mmHg vs 17.7 ± 0.25 mmHg; P = 0.002), 
as well as when combining the 2 visits (16.8 ± 0.24 mmHg 
vs 17.9 ± 0.24 mmHg; P = 0.001). Although IOP-lowering 
values favored the travoprost/timolol group compared to 
the dorzolamide/timolol group at all 4 PM time points, the 
differences did not reach statistical significance.Clinical Ophthalmology 2009:3 632
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As shown in Table 4, travoprost/timolol produced a 
mean IOP reduction from the untreated baseline ranging 
from 8.8 ± 0.23 mmHg to 10.4 ± 0.25 mmHg, whereas 
dorzolamide/timolol produced a mean IOP reduction ranging 
from 8.2 ± 0.21 mmHg to 9.3 ± 0.25 mmHg. Figure 2 shows 
that the mean diurnal IOP reductions in the travoprost/
timolol group were significantly greater than those in the 
dorzolamide/timolol group at Week 2 and Week 6 (P  0.05 
for each).
safety
The adverse events, related to the use of the study drugs, 
observed at an incidence of greater than 1% in the two 
treatment arms are described in Table 5. The most common 
treatment-related ocular adverse event was mild eye irritation, 
occurring in 5.7% of patients in the travoprost/timolol group 
and in 4.3% of patients in the dorzolamide/timolol group. 
More patients in the travoprost/timolol group than in the 
dorzolamide/timolol group experienced hyperemia, generally 
of mild severity and described as conjunctival (5.7% vs 0.6%, 
respectively; P = 0.0096) or ocular hyperemia (5.1% vs 
0.6%, respectively; P = 0.0182). No serious treatment-related 
adverse events were reported in either group.
In the travoprost/timolol group, 4 patients (2.5%) stopped 
the study medication and were discontinued from the study 
due to ocular treatment-related events (hyperemia, eye pain, 
conjunctivitis, and hypersensitivity). In the dorzolamide/
timolol group, 1 patient (0.6%) stopped the study medication 
and was discontinued from the study due to a nonocular event 
(hallucination, considered not related to treatment).
Discussion
In this study, we compared the IOP-lowering efficacy 
of two fixed combinations, travoprost 0.004%/timolol 
0.5% dosed once daily in the morning and dorzolamide 
2%/timolol 0.5% dosed twice daily, in patients with open-
angle glaucoma or ocular hypertension. These results were 
expected to show that travoprost/timolol would have superior 
Table 1 Baseline demographics – safety population (n = 319)
Total Travoprost/Timolol Dorzolamide/Timolol P-valuea
N % N % N %
Total 319 100.0 157 100.0 162 100.0
Age (years)
  65 190 59.6 92 58.6 98 60.5 0.730
  65 129 40.4 65 41.4 64 39.5
Age (65 years)
  65 to 75 89 69.0 44 67.7 45 70.3 0.748
  75 to 85 40 31.0 21 32.3 19 29.7
Sex
  Male 122 38.2 58 36.9 64 39.5 0.638
  Female 197 61.8 99 63.1 98 60.5
Race
  Caucasian 319 100.0 157 100.0 162 100.0
Iris color
  Blue 84 26.3 39 24.8 45 27.8 0.582
  Brown 153 48.0 72 45.9 81 50.0
  green 32 10.0 18 11.5 14 8.6
  grey 20 6.3 13 8.3 7 4.3
  hazel 30 9.4 15 9.6 15 9.3
Diagnosis
  Ocular hypertension 52 16.3 24 15.3 28 17.3 0.784
  Open-angle glaucoma 243 76.2 119 75.8 124 76.5
    Open-angle glaucoma 
with pigment dispersion
5 1.6 3 1.9 2 1.2
    Open-angle glaucoma 
with pseudoexfoliation
19 6.0 11 7.0 8 4.9
Notes: Travoprost/Timolol = travoprost 0.004%/timolol 0.5%. Dorzolamide/Timolol = dorzolamide 2%/timolol 0.5%. 
aP-value from chi-square or Fisher’s exact test.Clinical Ophthalmology 2009:3 633
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Table 2 Intraocular pressure- (IOP-) lowering medication at screening – safety population (n = 319)
IOP-lowering medication Travoprost/Timolol (N = 157) Dorzolamide/Timolol (N = 162)
Na % Na %
Alfa-agonists (AA) 4 2.5 3 1.9
Beta-blockers (BB) 25 15.9 20 12.3
Carbonic anhydrase inhibitors (CAi) 60 38.2 60 37.0
Combination therapyb 47 29.9 50 30.9
Pilocarpine 3 1.9 3 1.9
Prostaglandin analogues (Pg) 34 21.7 44 27.2
Notes: aThe total number of patients in each column is higher than N because patients could be classified under more than one category of IOP-lowering medication.
bCombination therapy = fixed ophthalmic combinations of BB + CAi, BB + Pg, or BB + AA.   Travoprost/Timolol = travoprost 0.004%/timolol 0.5%. Dorzolamide/Timolol = 
dorzolamide 2%/timolol 0.5%
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Figure 1 Mean diurnal intraocular pressure (iOP) (± standard error) across visits.
Notes: *P  0.05 for difference in mean diurnal IOP.    Travoprost/Timolol = travoprost 0.004%/timolol 0.5%.  Dorzolamide/Timolol = dorzolamide 2%/timolol 0.5%
efficacy to dorzolamide/timolol, based on previous studies 
of travoprost alone compared to the fixed combination of 
dorzolamide/timolol, in which travoprost produced superior 
IOP reductions10,11 and fewer treatment failures.12
Our results show that during the day, the fixed combination 
travoprost/timolol produced a higher IOP-lowering efficacy 
than the fixed combination dorzolamide /timolol dosed twice 
daily, at each visit as well as when pooling data across visits. 
The observed differences were both statistically significant 
and clinically meaningful; there was a consistent difference 
of 0.8 mmHg (P  0.05) between the two groups.
Travoprost/timolol produced lower mean diurnal IOP than 
dorzolamide/timolol. Diurnal reduction of IOP has been asso-
ciated with a reduced risk of progression of glaucoma in several 
studies. The Early Manifest Glaucoma Trial showed that every 
1 mmHg of IOP reduction was associated with approximately 
a 10% reduction in risk of glaucoma progression.13
Mean IOP with travoprost/timolol was at least 1.0 mmHg 
lower than with dorzolamide/timolol at 9 AM; these 
differences were statistically significant at both the Week 2 
and Week 6 visits. These results were not unexpected because 
at the 9 AM time points (12 hours after dosing dorzolamide/
timolol and 24 hours after dosing travoprost/timolol), 
dorzolamide was likely not to be as effective since its dura-
tion of action is less than 8 hours,14 whereas travoprost has 
been shown to be effective more than 48 hours after dosing.15 
A tendency for lower IOP in the travoprost/timolol group 
was uniformly present both at Week 2 and Week 6 and for the 
pooled data, with the difference between the two treatment 
arms  0.5 mmHg at the 4 PM time points. Because these 
time points measured IOP control only 7 hours after dosing, 
both travoprost/timolol and dorzolamide/timolol were likely 
to be effective and therefore no significant difference between 
treatments was observed.Clinical Ophthalmology 2009:3 634
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Table 3 Mean intraocular pressure (IOP) (mmHg) across time points – intent-to-treat population (n = 316)
Baseline Week 2 Week 6 Combined
9 AM 4 PM 9 AM 4 PM 9 AM 4 PM 9 AM 4 PM Diurnal
Travoprost/Timolol
  Mean 26.9 25.1 17.0 16.2 16.6 16.2 16.8 16.2 16.5
  se 0.19 0.19 0.26 0.26 0.26 0.26 0.24 0.24 0.23
  n 154 154 154 154 154 154 154 154 154
Dorzolamide/Timolol
  Mean 27.0 25.1 18.0 16.9 17.7 16.6 17.9 16.8 17.3
  se 0.19 0.19 0.25 0.25 0.25 0.25 0.24 0.24 0.23
  n 162 162 162 161 162 161 162 161 162
Difference
  Mean −0.1 0.0 −1.0 −0.7 −1.2 −0.5 −1.1 −0.6 −0.8
  se 0.27 0.27 0.36 0.36 0.36 0.36 0.34 0.34 0.32
Upper 95% CL 0.4 0.5 −0.3 0.0 −0.4 0.2 −0.4 0.1 −0.2
Lower 95% CL −0.7 −0.5 −1.7 −1.4 −1.9 −1.2 −1.7 −1.2 −1.5
P-value 0.652 0.987 0.006 0.066 0.002 0.192 0.001 0.090 0.011
Notes: Travoprost/Timolol = travoprost 0.004%/timolol 0.5%. Dorzolamide/Timolol = dorzolamide 2%/timolol 0.5%.
aBaseline is the average of the two eligibility visits if both values were not missing, otherwise the nonmissing value of the two visits was used. Combined = results pooled across  Week 2 
and Week 6. Combined diurnal = mean IOP of all 4 time points (9 AM and 4 PM at Week 2 and Week 6). Estimates based on least squares means using repeated measures 
analysis of variance. Baseline estimates obtained from separate model. P-values and confidence limits were based on repeated measures analysis of variance.
Abbreviations: CL, confidence limit; SE, standard error.
Travoprost/timolol produced statistically significant 
and clinically relevant mean IOP reductions from baseline 
ranging from 8.8 mmHg (35.3%) to 10.4 mmHg (38.5%). 
This is consistent with prior studies in which mean IOP 
reductions ranged from 6.9 to 8.6 mmHg,4 7.4 to 9.4 mmHg,5 
and 8.8 to 11.5 mmHg.6 Dorzolamide/timolol also produced 
significant and relevant mean IOP reductions from baseline, 
ranging from 8.2 mmHg (32.5%) to 9.3 mmHg (34.5%). 
This is also consistent with prior data in which mean IOP 
reductions ranged from 7.7 to 9.0 mmHg.7
IOP values at Weeks 2 and 6 varied between 16.2 and 
17.0 mmHg for travoprost/timolol and between 16.6 and 
18.0 mmHg for dorzolamide/timolol. The narrower range 
for travoprost 0.004%/timolol 0.5% (0.8 mmHg) suggests 
less fluctuation of IOP during the day. Asrani and colleagues 
suggested that eyes with greater diurnal IOP variation are at 
increased risk of visual field progression.8 Bergea also found 
that visual field progression was more likely in eyes with higher 
versus lower diurnal IOP variation.9 However, since the data on 
the relationship between diurnal IOP fluctuation and progression 
of glaucoma are scarce, the clinical relevance of the narrower 
range observed in this study remains to be confirmed.
Both therapies evaluated in this study offer numerous benefits 
that have been previously described for fixed combination 
products.3 Compared to dorzolamide/timolol, the fixed 
combination travoprost/timolol offers the additional advantage 
of once-daily dosing. Adherence to therapy improves as the 
frequency of dosing decreases.16 Once-daily dosing is preferred 
by glaucoma patients and glaucoma specialists alike.
Aside from eye irritation, which was the most prevalent 
adverse event in both groups, the most frequent ocular event 
in the travoprost/timolol subjects was conjunctival hyperemia. 
Eye pruritus was the most frequent ocular event reported in 
the subjects receiving dorzolamide/timolol. The statistically 
Table 4 Descriptive mean intraocular pressure (iOP) and mean 
IOP change from baseline (mmHg) – intent-to-treat population 
(n = 316)
Treatment Week 2 Week 6
9 AM 4 PM 9 AM 4 PM
Travoprost/Timolol
  Mean iOP 17.0 16.2 16.6 16.2
  se iOP 0.29 0.26 0.26 0.25
  Mean iOP Change −9.9 −8.8 −10.4 −8.9
  se iOP Change 0.25 0.23 0.25 0.25
  n 154 154 154 154
Dorzolamide/Timolol
  Mean iOP 18.0 16.9 17.7 16.6
  se iOP 0.25 0.23 0.27 0.24
  Mean iOP Change −9.0 −8.2 −9.3 −8.5
  se iOP Change 0.24 0.21 0.25 0.23
  n 162 161 162 161
Notes: Travoprost/Timolol = travoprost 0.004%/timolol 0.5%. Dorzolamide/ 
Timolol = dorzolamide 2%/timolol 0.5%. Descriptive statistics were based on the 
least square estimates.
Abbreviation: se, standard error.Clinical Ophthalmology 2009:3 635
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Figure 2 Mean diurnal intraocular pressure (iOP) (± standard error) reduction from baseline.
Notes: *P  0.05 for difference in IOP reduction from baseline.   Travoprost/Timolol = travoprost 0.004%/timolol 0.5%.  Dorzolamide/Timolol = dorzolamide 2%/timolol 0.5%
significant differences found between treatment groups in 
the rates of hyperemia do not represent an untoward safety 
issue. The incidence of these side effects is consistent with 
the known safety profile of  travoprost 0.004%/timolol 0.5%. 
Hyperemia is not unexpected since it is observed frequently 
with the use of all prostaglandin analogues. Eye pruritus 
was also an expected ocular event.
In summary, the fixed combination travoprost 0.004%/
timolol 0.5% dosed once daily in the morning demonstrates 
superior IOP-lowering efficacy compared to dorzolamide 
2%/timolol 0.5% dosed twice daily in patients with ocular 
hypertension or open-angle glaucoma. Both combinations 
offer the benefits of fixed-combination therapy, but travo-
prost/timolol offers these benefits with the convenience of 
once-daily dosing, an attribute valued by both glaucoma 
patients and their physicians because it encourages patient 
compliance.16
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